A clinical study to evaluate the biological effects of preoperative intravenous administration of VCN-01 in patients prior to surgical resection of high-grade brain tumours
Latest Information Update: 25 Mar 2024
At a glance
- Drugs VCN 01 (Primary)
- Indications Glioma
- Focus Adverse reactions; Pharmacodynamics
- Acronyms VCN-01 BRAIN
- 18 Sep 2023 Planned End Date changed from 1 Jul 2024 to 1 Jul 2025.
- 09 Jan 2023 According to a Theriva Biologics media release, this trial is funded by The Brain Tumour Charity and Cancer Research UK.
- 09 Jan 2023 According to a Theriva Biologics media release, first patient has been dosed in this study.